---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-23-000142"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:15:13.251277+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma issues 15K Series NC preferred shares to CEO with super-voting rights

## Summary
- Issued 15,000 Series NC preferred shares to CEO David Koos to settle $10,050 debt.
- Each Series NC share carries 334 votes, disproportionately high voting power.
- Issuance dilutes common stock voting power and has anti-takeover effect.
- Board authorized 20,000 shares of Series NC; 15,000 issued now.

## SEC filing metadata
- accession: 0001607062-23-000142
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 3.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706223000142/0001607062-23-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706223000142/rgbp032023form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-23-000142
- JSON: https://secwatch.observer/filing/0001607062-23-000142.json
- Plain text: https://secwatch.observer/filing/0001607062-23-000142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.